APPLICATION
ANDA077512
TYPE
ANDA
ORIGINAL APPROVAL
2012-09-12
LATEST ACTION
2025-03-03
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
ESCITALOPRAM OXALATEDiscontinued
ESCITALOPRAM OXALATE EQ 20MG BASE · TABLET · ORAL
ESCITALOPRAM OXALATEDiscontinued
ESCITALOPRAM OXALATE EQ 5MG BASE · TABLET · ORAL
ESCITALOPRAM OXALATEDiscontinued
ESCITALOPRAM OXALATE EQ 10MG BASE · TABLET · ORAL
Approval history
2025-03-03Labeling · Supplement 4 · standardAP
2025-03-03Labeling · Supplement 5 · standardAP
2013-11-15Labeling · Supplement 2 · standardAP
2013-05-20Labeling · Supplement 1 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.